10% Owner Converts $19M Preferred Stock into Common, Significantly Diluting Shares

summarizeSummary

1315 Capital II, L.P., a 10% owner, converted $19 million worth of Series C Convertible Preferred Stock into over 9.4 million common shares, representing a substantial increase in outstanding shares for Interpace Biosciences.

check_boxKey Events

• Major Preferred Stock Conversion

  1315 Capital II, L.P., a 10% owner, converted $19 million of Series C Convertible Preferred Stock into 9,405,941 shares of common stock.

• Significant Dilution

  The conversion represents a substantial increase in outstanding common shares, equivalent to over 235% of the company's current market capitalization.

• Part of Broader Capital Restructuring

  This conversion follows a similar event by another 10% owner and aligns with the "significant capital structure changes" disclosed in the company's January 20, 2026 8-K filing.

auto_awesomeAnalysis

This Form 4 filing details a significant capital structure event for Interpace Biosciences, where a major 10% owner, 1315 Capital II, L.P., converted $19 million of Series C Convertible Preferred Stock into 9,405,941 shares of common stock. This conversion, occurring on January 20, 2026, at a price of $2.02 per share, represents a massive dilution for existing common shareholders. This follows a similar conversion by another 10% owner (Ampersand 2018 Limited Partnership) reported on February 4, 2026, and aligns with the "significant capital structure changes" disclosed in the company's 8-K filing on January 20, 2026. While converting preferred stock can simplify the balance sheet, the sheer volume of new common shares introduced into the market creates substantial downward pressure on the stock price due to the significant increase in float. Investors should be aware of the ongoing dilution from these preferred stock conversions.